Spis treści:
Spis załączników:
SFA_2023_Pharmanova_SCC_Approval_espi.pdf (REPORT)
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
SFA_2023_Pharmanova_SCC_Approval_espi.pdf (REPORT)
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 196 | / | 2023 | ||||||||
| Date of issue: | 2023-11-07 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| Serbian Commission for Protection of Competition allowed deal with Pharmanova | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| “Sopharma” AD (the Company) notifies that the Serbian Commission for Protection of Competition has authorized Sopharma AD to acquire the manufacturer Pharmanova in stages. The deal will take place in several stages, starting with the acquisition of 25% of the company's capital. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| SFA_2023_Pharmanova_SCC_Approval_espi.pdfSFA_2023_Pharmanova_SCC_Approval_espi.pdf | Serbian Commission for Protection of Competition allowed deal with Pharmanova | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) |
||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2023-11-07 | Ognian Donev | Executive Director | |||
Źródło:Komunikaty spółek (ESPI)
